Author of

• 15301

  +

  P3.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 211)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Localized Disease - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15335

    +

    P3.02-034 - Utilization of Adjuvant Therapy Among Completely Resected Non-Small Cell Lung Cancer (NSCLC) Patients at Charleston Area Medical Center (ID 936)

    09:30 - 09:30  |  Author(s): S.J. Jubelirer
    • Abstract

    Background:
    Recently, adjuvant chemotherapy has become the standard of care for completely resected (R0) stage II and IIIA NSCLC patients; up for debate is the use of adjuvant therapy for stage IB. This retrospective study examined the therapies used in completely resected NSCLC patients.
    
    Methods:
    Information was initially gathered from the CAMC Cancer Registry which recorded nearly 2,500 occurrences of lung cancer during the study period (2005-2012). Those with completely resected (R0) stage IB (tumor size ≥ 4 cm) through IIIA (R0) NSCLC were selected for further review. Patients who did not receive preoperative therapy were included.
    
    Results:
    Meeting inclusion criteria were 171 patients, 96% Caucasian, with an average age of 66 ± 10 years (range 40-86). The majority were male (66%), 63% were married, and 55% had Medicare/Medicaid and most underwent a lobectomy (82%) Stages included IB (26%), IIA (23%), IIB (35%), and IIIA (16%), with 46% adenocarcinoma and 42% squamous cell. Adjuvant treatment type by stage is presented in Table 1. The majority of those not receiving treatment refused or elected observation (52%), while 16% were not treated due to comorbidities and 12% expired within 2 months of surgery. Logistic regression revealed that those who were treated were age < 65 years (odds ratio 3.3, CI 1.6-7.1, p = .002), stage IIIA (odd ratio 2.0, CI 1.3-2.9, p < .0005) and stage IIB (odd ratio 1.3, CI 1.0-1.7, p < .03).

    Treatment by stage for completely resected NSCLC

    	Stage
    	IB	IIA	IIB	IIIA
    	n(%)
    Treatment
    No Treatment	33(73.3)	24(60)	31(52.5)	6(22.2)
    Chemotherapy
    Cisplatin-based	7(15)	9(22.5)	12(20.3)	9(33.3)
    Carboplatin-based	4(8.9)	6(15)	9(15.3)	2(7.4)
    Sequential chemo/RT	0(0)	1(2.5)	1(1.7)	0(0)
    Concurrent chemo/RT	0(0)	0(0)	6(10.2)	7(25.9)
    RT alone	1(2.2)	0(0)	0(0)	3(11.1)

    
    
    Conclusion:
    Adjuvant therapy was seen more in stages IIB and IIIA. Stage IIIA received the highest rate of radiation. Of the patients who underwent treatment the majority received treatment that is compliant with NCCN guidelines. Unfortunately only 2 of the patients who received treatment were part of a clinical trial. The proportion of patients treated, was similar to the NCCN Outcomes Data Project of Zornosa C, et al.